Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …

Despite significant progress in breast cancer (BC) therapy, it is globally the most commonly
diagnosed cancer and leads to the death of over 650,000 women annually. Androgen …

Abstract Estrogen receptor-positive (ER+) breast cancer accounts for approximately 75% of
all breast cancers. Endocrine therapies, including selective ER modulators (SERMs) …

Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of
cancer death among women worldwide. Globally, BC is the second most frequent cancer …

Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-
dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in …

CDK4/6 inhibitors have become game-changers in the treatment of estrogen receptor-
positive (ER+) breast cancer, and in combination with endocrine therapy are the standard of …

Abstract Three-dimensional (3D) epigenome remodeling is an important mechanism of gene
deregulation in cancer. However, its potential as a target to counteract therapy resistance …